News | Stents Bioresorbable | July 19, 2016

Good Samaritan Hospital First on West Coast to Offer Absorb Bioresorbable Stent

Retired microbiology professor first California patient to receive fully dissolving, bioresorbable stent following recent FDA approval

Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles

July 19, 2016 — Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery disease (CAD) Abbott's Absorb dissolving heart stent. Absorb is a drug-eluting coronary stent that dissolves, completely and naturally, in the body over time.

The stent treats coronary artery disease in a similar fashion to a metallic stent, propping the diseased vessel open to restore blood flow, but then disappears after the artery is healed, leaving no metal behind to restrict natural vessel motion.

Steven Burstein, M.D., interventional cardiologist and medical director of the Cardiac Catherization Laboratory at Good Samaritan Hospital, was the first on the West Coast to implant the Absorb stent to patient Ernest Matson, 69, a retired microbiology professor at the University of Guam, on July 11th. 

According to the National Heart, Lung and Blood Institute, CAD is the most common type of heart disease. CAD is a condition in which the arteries that supply blood to the heart become narrowed or blocked by a buildup of plaque. Plaque is made up of fat, cholesterol, calcium and other deposits that accumulate on the inner wall of the artery. Over time, the plaque hardens and narrows the coronary arteries, limiting the flow of oxygen-rich blood to the heart muscle. Areas of plaque can also rupture, causing a blood clot to form on the surface of the plaque. When blood flow to the heart is reduced or blocked, angina (chest pain) or a heart attack can occur.

While stents are traditionally made of metal, the Absorb stent is made of a naturally dissolving material similar to dissolving sutures. Absorb disappears completely in about three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants.

"With outcomes equivalent to those of the best drug-eluting metallic stents, the Absorb scaffolding will dissolve within 18 to 24 months leaving behind a normal and natural vessel," said Burstein.  "This will not preclude further stenting or bypass surgery and may in fact make these future procedures, if indicated, easier to perform."

For more information: www.abbottvascular.com

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th